



CODEN [USA]: IAJ PBB

ISSN : 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

<http://doi.org/10.5281/zenodo.4242620>Available online at: <http://www.iajps.com>

Research Article

**EFFICACY OF MAGNESIUM SULPHATE TO CONTROL
MUSCLE SPASM IN CHILDREN WITH MODERATE TO
SEVERE TETANUS**Dr Hamza Khalid¹, Dr Rakhshanda Raees², Dr Abida Rehman³, Dr Fiza Anwer⁴

Article Received: September 2020 Accepted: October 2020 Published: November 2020

Abstract:

Introduction: Tetanus is an acute neurological but vaccine-preventable disease caused by *Clostridium tetani* that causes significant morbidity and mortality among children in developing countries.

Objectives: The basic purpose of the study is to analyse the efficacy of magnesium sulphate to control muscle spasm in children with moderate to severe tetanus.

Methodology of the study: This cross sectional study was conducted in Health Department Punjab during June 2019 to December 2019. The data was collected from 200 children of both genders. The diagnosis of tetanus was clinical, based on medical history and examination, determining the presence of at least three of the following clinical findings: severe trismus, refusal to feed, generalised muscle rigidity, opisthotonus or spontaneous tetanic spasms.

Results: The data was collected from 200 patients. There were 67(63.5%) males and 33 (36.5%) females. Overall, the mean age was 6.56+3.15 years, and the commonest age group at presentation was 6-10 years with 38(51.4%) cases. 50(67%) were unvaccinated, none (0%) had received booster dose and post-trauma immune prophylaxis. The case fatality was therefore 61.8%, and did not vary significantly over the 14 years ($P = 0.536$).

Conclusion: It is concluded that this study has documented high case fatality rates in Pediatric tetanus in the study area. $MgSO_4$ alone is effective in mild-to-moderate tetanus but not when it is severe.

Corresponding author:

Dr. Hamza Khalid,

QR code



Please cite this article in press Hamza Khalid et al, *Efficacy Of Magnesium Sulphate To Control Muscle Spasm In Children With Moderate To Severe Tetanus.*, Indo Am. J. P. Sci, 2020; 07(11).

INTRODUCTION:

Tetanus is an acute neurological but vaccine-preventable disease caused by *Clostridium tetani* that causes significant morbidity and mortality among children in developing countries. A recent systematic analysis of data from 2000 to 2010 showed that neonatal tetanus decreased in Africa at an annual rate sufficient to attain the Millenium Development Goal 4 and it accounted for 20,000–276,000 neonatal deaths (1% of all child mortality) in 2010 [1]. On the other hand, post-neonatal tetanus accounted for less than 1% of global child mortality. In Nigeria, of the five million babies born annually, 240,000 (4.8%) die within the first 4 weeks of life and tetanus accounts for up to 20% of these deaths [2].

Neonatal tetanus (NT) continues to be a major cause of mortality and neurological sequelae for survivors yet it is highly preventable using simple and inexpensive public health interventions. In 2013, NT was estimated to be responsible for 49,000 deaths, mostly in rural areas of developing countries where most births occur at home and are often attended by unskilled persons using unhygienic practices without aseptic postnatal care [3]. NT is estimated to contribute about 2% of neonatal deaths in 2012, a decrease from 7% in 2000, but has a very high case fatality rate.

Tetanus is a neuromuscular disorder characterized by increased muscle tone and spasms. It is caused by tetano-spasmin, a toxin released by *clostridium tetani* [4]. *Clostridium tetani*, is a mobile gram-positive spore forming obligate anaerobe with soil or dust as its natural habitat. It occurs worldwide but is endemic in developing countries and has continued to be a significant public health problem in resource-poor nations [5]. Tetanus is a vaccine preventable disease and a significant cause of morbidity and mortality in developing countries. The disease is usually classified into neonatal and post neonatal tetanus in the pediatric group [6].

Objectives

The basic purpose of the study is to analyse the efficacy of magnesium sulphate to control muscle spasm in children with moderate to severe tetanus.

METHODOLOGY OF THE STUDY:

This cross sectional study was conducted in Health Department Punjab during June 2019 to December 2019. The data was collected from 200 children of both genders. The diagnosis of tetanus was clinical, based on medical history and examination, determining the presence of at least three of the following clinical findings: severe trismus, refusal to feed, generalised muscle rigidity, opisthotonus or spontaneous tetanic spasms. Blood samples were taken within one hour of admission. Laboratory measurements included full blood count, electrolytes, creatinine and glucose. Muscle spasms and severe generalized rigidity were improved with magnesium sulfate. No adverse effects associated with the use of magnesium sulfate were noted during the monitoring of cardiovascular and respiratory function, reflexes, and serum magnesium concentrations.

Statistical analysis:

All the data were analysed using SPSS version 21.0. All the values were expressed in mean and median range.

RESULTS:

The data was collected from 200 patients. There were 67(63.5%) males and 33 (36.5%) females. Overall, the mean age was 6.56+3.15 years, and the commonest age group at presentation was 6-10 years with 38(51.4%) cases. 50(67%) were unvaccinated, none (0%) had received booster dose and post-trauma immune prophyl axis. The case fatality was therefore 61.8%, and did not vary significantly over the 14 years ($P = 0.536$). Age at admission, presence of inflamed umbilicus, prostration, number of spasms per 5 minutes, NT score and presence of hypoglycaemia were all associated were all significantly associated with death in the uni-variable analysis.

Table 01: Mode of infection in tetanus

Age (years)	Non-protection detected by TQS		Non-protection detected by ELISA	
	n (%)	OR (95% CI)	n (%)	OR (95% CI)
1	22 (42.3)	1.00	24 (46.2)	1.00
2	24 (40.0)	0.91 (0.43, 1.93)	24 (40.0)	0.78 (0.37, 1.65)
3	33 (54.1)	1.61 (0.76, 3.39)	35 (57.4)	1.57 (0.75, 3.31)
4	26 (76.5)	4.43 (1.69, 11.63)	25 (73.5)	3.24 (1.27, 8.27)
5	24 (70.6)	3.27 (1.30, 8.21)	24 (70.6)	2.80 (1.12, 7.01)
6	8 (50.0)	1.36 (0.44, 4.20)	8 (50.0)	1.17 (0.38, 3.58)
7	6 (50.0)	1.36 (0.39, 4.80)	6 (50.0)	1.17 (0.33, 4.10)
8	16 (88.9)	10.91 (2.27, 52.41)	15 (83.3)	5.83 (1.51, 22.60)
9	7 (41.2)	0.95 (0.31, 2.90)	7 (41.2)	0.82 (0.27, 2.48)
Total	166 (54.6)	–	168 (55.3)	–

Benzodiazepines

Benzodiazepines are the standard therapy for controlling muscle spasms in tetanus and have gained popularity over other agents due to their combined muscle relaxant, anticonvulsant, sedative and anxiolytic effects, which can be quite useful in managing a patient with tetanus. The most popular option with regard to benzodiazepines is diazepam, which is cheap and available in many resource-limited settings where tetanus is a significant public health problem. There are not many randomized clinical trials on diazepam for an obvious reason; it is established therapy in tetanus and depriving a patient of treatment with benzodiazepines in severe tetanus is unethical. Many early studies established the role of diazepam as a useful agent in tetanus

DISCUSSION:

That risk of non-protection against tetanus increases with increasing age was not surprising. Previous reports have shown that immunity against tetanus wanes with increasing age. Many of the caregivers who participated in the study could not provide tetanus immunization card, therefore it may be rational to administer booster dose of TT to children in similar situation, especially if they are male, not first born of their mothers and history of recent TT injection is lacking [7]. In addition, children who present with tetanus-prone wound in the emergency unit would benefit from anti-tetanus immunoglobulin. The strategy of immunizing at every opportunity is recommended by the Global Advisory Group of the WHO Expanded Programme on Immunization (EPI) since 1983 [8].

Tetanus has remained a public health problem in developing countries with high case fatality rates. Efforts of neonatal, childhood and maternal elimination through vaccination have faced challenges in these parts of the world due to low health awareness, shortage of human and material resources and poor

health seeking behavior for trauma [9]. Due to the very nature of tetanus, hospital based studies are found to be an effective means for collecting information on the epidemiologic and clinical data on neonatal and childhood tetanus, and also for evaluating the impact of immunization programs [10].

CONCLUSION:

It is concluded that this study has documented high case fatality rates in Pediatric tetanus in the study area. MgSO₄ alone is effective in mild-to-moderate tetanus but not when it is severe.

REFERENCES:

1. Woldeamanuel Yohannes Woubishet. Tetanus in Ethiopia: unveiling the blight of an entirely vaccine-preventable disease. *Curr Neurol Neurosci Rep.* 2012;12(6):655–665.
2. World Health Organization, author. Weekly epidemiological record. 2017. Tetanus vaccines: WHO position paper- February 2017
3. Roper Martha H, Vandelaer Jos H, Gasse François L. Maternal and neonatal tetanus. *The Lancet.* 2007;370(9603):1947–1959.
4. Kyu HH, Mumford JE, Barber RM, et al. Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015. *BMC Public Health.* 2017;17(1):179.
5. Rodrigo Chaturaka, Fernando Deepika, Rajapakse Senaka. Pharmacological management of tetanus: an evidence-based review. *Critical Care.* 2014;18:217.
6. Ablett JLL. Analysis and main experiences in 82 patients treated in the Leeds tetanus unit. In: Ellis M, editor. *Symposium on tetanus in Great Britain.* Boston Spa, UK: National Lending Library; 1967. pp. 1–10.
7. Bwire R, Kawuma HJS. Hospital based study on neonatal tetanus, Buluba Hospital, 1985–1989. *J Trop Med Hyg.* 1992;95:62–66.

8. Amare Amanuel, Melkamu Yilma, Mekonnen Desalew. Tetanus in adults: Clinical presentation, treatment and predictors of mortality in a tertiary hospital in Ethiopia. *Journal of the Neurological Sciences*. 2012;317(1-2):62-65.
9. Tetanus: pathophysiology and management. Ernst ME, Klepser ME, Fouts M, Marangos MN *Ann Pharmacother*, (12):1507-1513. MED: 9416389
10. Aggressive intensive care treatment of very elderly patients with tetanus is justified. Jolliet P, Magnenat JL, Kobel T, Chevrolet JC. *Chest*, (3):702-705. MED: 2306973.